AbbVie leadership under scrutiny for Shire blunder
Jeffrey Clark - Posted: 11/23/2014
AbbVie wins the Shifting Gears award for 2014 with its on again, off again bid to acquire Shire for $54 billion.   Now, some are calling into question the credibility of AbbVies management for the blunder. AbbVie announced its intent to acquire Shire[...]
Edwards CEO on new heart valve technology
Jeffrey Clark - Posted: 11/19/2014
Edwards Lifesciences CEO Michael Mussallem talks with CNBC about how his company is helping patients recover quicker from heart valve surgery.
Next Sanofi CEO? The candidates
Jeffrey Clark - Posted: 11/19/2014
Its been two weeks since Sanofi let go of CEO Chris Viehbacher, ending an 8-year tenure at the leading drug company. Viehbacher leaves behind a trail of acquisitions, job cuts, expansion and R&D reform. More importantly, he left in his wake a tenuous[...]
Actavis, Allergan CEOs on CNBC; Ackman walks away with $2B
Jeffrey Clark - Posted: 11/18/2014
Bill Ackman’s Pershing Square hedge fund is set to receive a $2 billion consolation prize, even after partner Valeant Pharmaceuticals walks away from its hostile takeover bid for Allergan. Yesterday, Allergan announced a deal with Actavis for almost [...]
Actavis, Allergan look to push Valeant out of the picture
Jeffrey Clark - Posted: 11/17/2014
Actavis is nearing a deal to acquire Allergan in a move that could help shield Allergan from a hostile takeover by Valeant Pharmaceuticals. The Actavis and Allergan boards are expected to meet this week to review a cash & stock takeover. Ironically, [...]
Hologic CEO joins CNBC in studio, talks medical device tax
Jeffrey Clark - Posted: 11/17/2014
Hologic president & CEO Steve MacMillan joins CNBC in studio to share his opinion on the unintended consequences of the Affordable Care Act and the likelihood of overturning the medical device tax.
Pfizer CEO spurns US Treasury: We can still do an inversion deal
Jeffrey Clark - Posted: 11/13/2014
Pfizer CEO Ian Read makes no apologies for his interest in working a deal to move his tax home overseas.   Despite the U.S. governments attempt to discourage tax inversionslike the one Pfizer would have achieved by buying AstraZeneca Read says he is[...]
Johnson and Johnson CEO on CNBC in support of veterans
Jeffrey Clark - Posted: 11/13/2014
Johnson & Johnson CEO Alex Gorsky was on CNBCs Street Signs last week affirming the companys support for the American Corporate Partners (ACP)s public service campaign designed to increase awareness of ACP AdvisorNet, which offers business leaders a [...]
A detailed account of the firing of Sanofi CEO Chris Viehbacher
Jeffrey Clark - Posted: 11/10/2014
Bloomberg publishes a detailed minute by minute account of Sanofi CEO Chris Viehbachers firing. Was he not French enough?
Dendreon death spiral hits bottom, files for bankruptcy
Jeffrey Clark - Posted: 11/10/2014
Dendreon was once the darling of the life sciences industry. The Seattle-based company won approval for the first ever cancer vaccine in Provenge, single-handedly launching the immunotherapy category. Today, Dendreon is bankrupt. They have tried to c[...]
Ackman: Put Allergan up for auction
Jeffrey Clark - Posted: 11/10/2014
Judgment Day is December 18th and it is rapidly approaching for Allergan, Valeant and all the personalities wrapped up into this sage, including Valeant CEO Mike Pearson, Pershing Square investor Bill Ackman, and Allergan CEO David Pyott. The process[...]
Republicans win control of Congress, likely to repeal Medical Device Tax
Jeffrey Clark - Posted: 11/5/2014
The new Republican-controlled Congress is likely to be full of ambition in rolling back President Obamas policies.  That ambition may include some rhetoric aimed at repealing the Affordable Care Act.  The truth, however, is that unlikely to be entire[...]
NewLink Genetics enters Ebola race, has support of WHO
Jeffrey Clark - Posted: 11/4/2014
NewLink Genetics has the backing of the World Health Organization, which will send thousands of doses of NewLinks experimental Ebola vaccine to West Africa in January. Dr. Charles Link, NewLink Genetics Chairman, CEO & Chief Scientific Officer, provi[...]
Labcorp acquires Covance to combine testing and drug development
Jeffrey Clark - Posted: 11/3/2014
Laboratory Corporation of America, commonly known as Labcorp, has reported that it has entered into a definitive agreement to acquire Covance for $5.6 billion. Covance, headquartered in Princeton, NJ, will combine with the Burlington, NC based Labcor[...]
Viehbacher loses bid to save job, ousted as CEO of Sanofi
Jeffrey Clark - Posted: 10/29/2014
Sanofi fired its CEO Chris Viehbacher on Wednesday.  The move comes just days after it was learned that Viehbacher was fighting to keep his role at the French drug maker. The reason?  An uncommunicative management style, Chairman Serge Weinberg said.[...]
Amgen not splitting up, cutting workforce even deeper
Jeffrey Clark - Posted: 10/29/2014
One of the life sciences biggest companies is getting smaller. Amgen, this week, Monday said that it will cut an additional 5% of its workforce in addition to the 2,900 positions it had already projected it will lose as it restructures. The changes, [...]
Sanofi CEO Viehbacher makes case to save his job
Jeffrey Clark - Posted: 10/28/2014
Sanofi CEO Chris Viehbacher, is all of a sudden, fighting for his professional career. The company has struggled of late with tensions rising between the CEO and the Board of Directors. First came Sanofis plan to divest $8B in drugs, with board consu[...]
Valeant CEO believes Allergan misinforming the public
Jeffrey Clark - Posted: 10/22/2014
Valeant CEO Mike Pearson on the CNBC set talking about Valeant, Allergan and the struggle to make a deal. In this interview, Pearson alleges that Allergan made false and inflammatory statements over the course of the past few months.
Valeant CEO talks company performance as Allergan showdown looms
Jeffrey Clark - Posted: 10/22/2014
Michael Pearson, Valeant Pharmaceuticals CEO, breaks down the companys quarterly numbers and provides an outlook on future growth as the Allergan merger battle continues.
AbbVie/Shire deal officially off after US thwarts inversion benefits
Jeffrey Clark - Posted: 10/21/2014
For the first time, a company has cancelled its planned merger with a foreign partner for reasons related to tax inversion. After rationalizing its intent by stating obvious synergies between the two companies, AbbVie officials have now announced tha[...]
A challenge for a pharmaceutical company called ISIS
Jeffrey Clark - Posted: 10/17/2014
The editors at CNN asked a very poignant question today, partially relevant to the life sciences industry:  What if your business is called ISIS? Most in the life sciences are aware of ISIS Pharmaceuticals, the drug development firm in Carlsbad, CA l[...]
AbbVie reconsiders Shire deal amid US changes to tax inversions
Jeffrey Clark - Posted: 10/15/2014
Medtronic reaffirmed its commitment last week to acquire Covidien on the heels of the US federal government making it more difficult for companies to benefit from so-called tax inversion deals.  Medtronic believes there is enough strategic synergy to[...]
Chinese firm enters race to develop Ebola treatment
Jeffrey Clark - Posted: 10/14/2014
Ebola is now spreading beyond its stronghold in western Africa to more developed countries.  And, the world is reacting and responding with contingency plans, treatments and potential cures in fast track development. One Chinese drugmaker with close [...]
Becton Dickinson acquires Carefusion for $12B
Jeffrey Clark - Posted: 10/13/2014
Becton, Dickinson & Co. has agreed to buy CareFusion for $12.2 billion in a deal that could be finalized during the first half of next year.  Recent research and development activities at the two firms have focused on tools used to minimize patient-s[...]
Can Actavis save Allergan from Valeant? And, the Love Quadrilateral?
Jeffrey Clark - Posted: 10/8/2014
Will Actavis ride in as a white knight for Allergan? After being rebuffed by Allergan with a tepid offer last month, Actavis has returned with a more convincing strategy. Actavis is selling the promise of less cost cutting to fund the transaction, wh[...]
Edwards CEO on new heart [...]
Edwards Lifesciences CEO Michael Mussallem talks with CNBC about how his company is helping patients[...]
Actavis, Allergan CEOs on[...]
Bill Ackman’s Pershing Square hedge fund is set to receive a $2 billion consolation prize, even afte[...]
Becton Dickinson acquires[...]
Becton, Dickinson & Co. has agreed to buy CareFusion for $12.2 billion in a deal that could be final[...]
Ebola reaches US, life sc[...]
Ebola has found its way to the United States. The first confirmed US case of Ebola was announced in [...]
Astellas driving to becom[...]
Ken Jones, CEO of Astellas Pharmaceuticals EMEA, talks about the company’s leadership journey as it [...]